Database

Being Health is a psychiatrist-led mental health practice that leverages the best of psychiatry, novel treatments (ketamine treatments), psychotherapy, functional medicine and wellness services to help people feel better in their everyday state of being.

The Awareness Lectures on Psychedelic Science (ALPS) returns for its fourth edition on 11-12 October 2024 in the city of Aarau, located in the canton of Aargau, Switzerland.

This review (2024) examines the potential therapeutic mechanisms of action for alcoholism (AUD) treatment using 5-MeO-DMT. It highlights that 5-MeO-DMT can induce mystical experiences and ego-dissolution, leading to increased psychological flexibility and mindfulness, which may alleviate AUD symptoms. Additionally, preliminary evidence suggests that 5-MeO-DMT modulates neural oscillations and exhibits neuroplasticity and anti-inflammatory properties, indicating its potential clinical implications for AUD and related psychiatric comorbidities.

The reMind Psychedelics Business Forum will bring together entrepreneurs, business owners, investors, policymakers, and healthcare professionals at the forefront of the rapidly evolving psychedelics marketplace.

This cross-sectional study (n=113) compared experienced psychedelic users (n=56) to nonusers (n=57) regarding neural responses to Self-name stimuli, known for activating self-representation. While no difference in P300 amplitude was found between users and nonusers for Self- or Target-names, users exhibited increased P300 amplitude for Other-names. Additionally, users showed a smaller increase in P300 amplitude for task-relevant stimuli compared to nonusers, suggesting potential alterations in attentional resource allocation rather than prolonged changes in self-representation due to psychedelic use.

This double-blind, placebo-controlled study (n=10) assesses the safety and efficacy of repeated pulse administration of psilocybin (10mg/70kg, 3x in 15 days) in cluster headache patients. Following the initial trial, eligible participants received a psilocybin pulse at least 6 months later and kept headache diaries for 8 weeks. Results indicate a significant reduction in cluster attack frequency following the psilocybin pulse, suggesting potential therapeutic benefits.

Join the Medicinal Psychedelics Conference on July 25, 2024, in Melbourne. Explore therapeutic potential, connect with experts, and discuss the future of mental healthcare.

In this recap of the latest psychedelic research from March 2024 with a look at meditation, SSRIs, and safety of psychedelics, and 17 more studies.

This double-blind, randomized study (n=27) assessed the antidepressant effects of a novel oral prolonged-release formulation of racemic ketamine (KET01) in TRD patients as add-on therapy. Patients received either 160 mg/day or 240 mg/day KET01 or placebo for 14 days, with the primary endpoint being the change in Montgomery-Åsberg Depression Rating Scale (MADRS) scores from baseline to day 15. Results suggest a positive trend towards antidepressant efficacy with 240 mg/day KET01.

This prospective cohort study (n=124, 62 older adults) investigates the effects of a guided psychedelic group session on well-being in older adults (OA) compared to younger adults (YA). Mixed linear regression analyses show significant improvements in well-being in both groups, particularly amplified in OA with a history of psychiatric diagnosis. Acute subjective psychedelic effects were attenuated in OA compared to YA, but a psychosocial measure of Communitas emerged as a predictor in OA, indicating the potential value of relational components in psychedelic group settings for OA.